Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
NCT04172805Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2020
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, toripalimab in soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Started Mar 2020; status: completed.
02
Drugs
anlotinibtoripalimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04172805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172805.